Elevated levels of the carcinoembryonic antigen (CEA) have been linked to an unfavorable cancer prognosis [24], prompting investigations into CEA-targeted therapies for lung [25], breast, pancreatic, and gastric cancers [26,27], especially colorectal cancer (CRC) [28]. This evidence concerns the gene CEACAM5 and colorectal cancer.